THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 127 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $9,158,782 | -24.1% | 1,061,177 | -9.0% | 0.00% | 0.0% |
Q2 2023 | $12,064,608 | -6.2% | 1,165,662 | -1.7% | 0.00% | -50.0% |
Q1 2023 | $12,868,205 | +100440.7% | 1,186,009 | +4.0% | 0.00% | 0.0% |
Q4 2022 | $12,799 | -99.9% | 1,140,753 | +5.7% | 0.00% | 0.0% |
Q3 2022 | $10,941,000 | +17.5% | 1,079,087 | +5.0% | 0.00% | +100.0% |
Q2 2022 | $9,310,000 | -3.6% | 1,027,664 | +1.7% | 0.00% | 0.0% |
Q1 2022 | $9,657,000 | -16.1% | 1,010,163 | -3.0% | 0.00% | 0.0% |
Q4 2021 | $11,512,000 | +123.7% | 1,041,832 | +49.8% | 0.00% | 0.0% |
Q3 2021 | $5,146,000 | -62.0% | 695,504 | -25.4% | 0.00% | -50.0% |
Q2 2021 | $13,536,000 | -20.9% | 932,268 | +11.2% | 0.00% | -33.3% |
Q1 2021 | $17,110,000 | +27.6% | 838,363 | +11.1% | 0.00% | +50.0% |
Q4 2020 | $13,407,000 | +22.9% | 754,485 | +2.2% | 0.00% | 0.0% |
Q3 2020 | $10,912,000 | -27.9% | 738,095 | +2.3% | 0.00% | -33.3% |
Q2 2020 | $15,142,000 | -8.9% | 721,433 | +0.3% | 0.00% | -25.0% |
Q1 2020 | $16,617,000 | -47.5% | 719,072 | -41.2% | 0.00% | +33.3% |
Q4 2019 | $31,654,000 | +165.4% | 1,222,696 | +99.7% | 0.00% | 0.0% |
Q3 2019 | $11,929,000 | +24.7% | 612,399 | +4.6% | 0.00% | +50.0% |
Q2 2019 | $9,565,000 | -22.4% | 585,741 | +7.7% | 0.00% | -33.3% |
Q1 2019 | $12,333,000 | -51.5% | 544,029 | -45.3% | 0.00% | -25.0% |
Q4 2018 | $25,446,000 | +72.6% | 994,448 | +120.4% | 0.00% | 0.0% |
Q3 2018 | $14,741,000 | +49.5% | 451,221 | +3.8% | 0.00% | +33.3% |
Q2 2018 | $9,859,000 | +3.5% | 434,721 | +10.6% | 0.00% | 0.0% |
Q1 2018 | $9,530,000 | -8.5% | 393,009 | +5.2% | 0.00% | -25.0% |
Q4 2017 | $10,416,000 | -15.6% | 373,476 | +3.7% | 0.00% | -20.0% |
Q3 2017 | $12,335,000 | -12.4% | 360,259 | +1.9% | 0.01% | -16.7% |
Q2 2017 | $14,085,000 | +15.8% | 353,550 | +7.0% | 0.01% | +20.0% |
Q1 2017 | $12,160,000 | +22.2% | 330,280 | +5.8% | 0.01% | 0.0% |
Q4 2016 | $9,949,000 | +3.2% | 312,103 | +17.3% | 0.01% | 0.0% |
Q3 2016 | $9,639,000 | +73.0% | 266,000 | +8.3% | 0.01% | +66.7% |
Q2 2016 | $5,571,000 | +53.4% | 245,586 | +27.1% | 0.00% | +50.0% |
Q1 2016 | $3,632,000 | +24.6% | 193,239 | +8.6% | 0.00% | 0.0% |
Q4 2015 | $2,915,000 | +56.9% | 177,899 | +5.1% | 0.00% | +100.0% |
Q3 2015 | $1,858,000 | -11.9% | 169,201 | +4.5% | 0.00% | 0.0% |
Q2 2015 | $2,108,000 | -11.2% | 161,973 | +18.3% | 0.00% | 0.0% |
Q1 2015 | $2,375,000 | +17.9% | 136,904 | +1.3% | 0.00% | 0.0% |
Q4 2014 | $2,015,000 | -33.7% | 135,087 | +2.5% | 0.00% | -50.0% |
Q3 2014 | $3,037,000 | -26.6% | 131,760 | +1.5% | 0.00% | -33.3% |
Q2 2014 | $4,139,000 | – | 129,835 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
King Wealth Management Group | 22,500 | $583,000 | 0.15% |
Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |